Non-Hodgkin lymphoma
| Non-Hodgkin lymphoma | |
|---|---|
| Other names | Non-Hodgkin disease |
| Micrograph of mantle cell lymphoma, a type of non-Hodgkin lymphoma. Terminal ileum. H&E stain. | |
| Specialty | Hematology and oncology |
| Symptoms | Enlarged lymph nodes, fever, night sweats, weight loss, tiredness, itching |
| Usual onset | 65–75 years old |
| Risk factors | Poor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity, Epstein-Barr virus infection |
| Diagnostic method | Bone marrow or lymph node biopsy |
| Treatment | Chemotherapy, radiation, immunotherapy, targeted therapy, stem cell transplantation, surgery, watchful waiting |
| Prognosis | Five-year survival rate 71% (USA) |
| Frequency | 4.3 million (affected during 2015) |
| Deaths | 231,400 (2015) |
Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow-growing while others are fast-growing. Unlike Hodgkin lymphoma, which spreads contiguously, NHL is largely a systemic illness.